MIAMI, FL--(Marketwired - Dec 29, 2014) - Novus Acquisition & Development Corp (OTC PINK: NDEV), wholly owned subsidiary Novus Medical Group, Inc., a service provider of the health and wellness savings plan, "Novus MedPlan," announces that it has retained PR Revolution (http://www.prrevolution.com) to build a proprietary software platform to handle rapid growth.
"Because of our vast response to the Novus MedPlan enrollment, which opened in October, Novus has retained PR Revolution to rebrand the current Novus Medical Group website to help facilitate our growth. The new website will allow patients to be connected to providers in a seamless fashion," said Frank Labrozzi, Chairman of Novus. "The benefits of our software will allow Novus to continue to meet the needs of our growing Provider and Patient network and we anticipate the completion of the software in January." In addition, the Company is moving forward with the filing of the Form 10 with SEC to be recognized as a fully reporting OTCQB company in January 2015.
"We are excited to have been awarded the development project for Novus MedPlan. This is an exciting project for our entire team and we are looking forward to the final product," said Adam Segall, President of PR Revolution.
About Novus
Novus Acquisition & Development Corp. ("Novus") provides health insurance and related insurance solutions to the medical marijuana industry in states where legal programs exist. The Company also plans to offer physicians' education programs, pharmaceutical R&D, compliance, and business development services within the industry.
NDEV will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violates the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The products and statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on this press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to the Company. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.